The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The States will drive the sp...gla
Great news for Covid 19 sufferers, great news for investors...good times ahead guys :)
"Ensifentrine also has potential applications in cystic fibrosis, asthma and other respiratory diseases"...... I wonder what other respiratory diseases they have in mind.
Would be good to see this back up to £1.50 plus..
This presentation imo puts a bit more meat on the bone on the directional thinking of the management. Strategic partnerships to maximise the commercial value. Things are looking good..
August corporate presentation on the website, check it out. Interesting reading, massive potential $$$
I do hope so Buddy.
A short trial/feasibilty study on using Ensifentrine on covid 19 survivors with breathing issues would be welcome. I have no medical back ground so maybe ensifentrine would not help. It would be nice to get an out of the blue rns about this, i can but dream...
Atb Rhodi, i understand your decision completely and i wish you well on your future investments.
Kind regards
If we get through P3 and to market i wonder what the sp will be? Hard to estimate, lots of variables but it will be much higher...
Guys, a sigh of relief, I haven't recommended a strong buy in quite a while.
Full steam ahead ,The sp should start to gain traction :) This drug clearly works and its a mega bucks market , i can see clearer skies ahead!
Interesting movement in the States, could there be news re C19? or P3 funding? who knows but its nice to see a uplift anyway. With regards to contacting the company as a pi i believe it is a fruitless exercise as no response will be the outcome, being a II is a different matter. The AGM is our only opportunity.
50-60p is still a terrible sp, once P3 funding is understood and completed we may get a reasonable uplift hope past a quid, which is still poor...
Guys, for info, new presentation on the vrp website dated 1st June.
Will the company explore the possibility that rpl554 could have a therapeutic effect for survivors of Covid, not likely i think but you just never know!
All eyes on financing now for P3.
Its a long and winding road this share. I don't think any PI will get any news other than from RNS or other media articles...excellent test results, dreadful share price....go figure....the remedy: funding clarity and partnerships! A stiff drink is needed for the nerves lol
I believe management should give some clarification to the market around the compound and C19 and if there is a intention to explore this avenue or clarify that in their opinion our compound would be of no benefit. I believe the rise in sp last week might of been in anticipation of this..
Looking forward to the 30th. I am hoping that ensifentrine has the potential to aid covid 19 survivors and if so, vrp becomes more attractive.
Nice chunky buys, could we get a nice unexpected RNS? Well hopefully the uptick continues..
A lot of sizeable buys today and a tick up on both sides of the pond, interesting...
Rhodi, the Chair is still on the vrp website.
It will be interesting to know if there's been consideration in the possibility that Ensifentrine could be of any benefit to those poor people who may be left with lung damage at the end of this horrendous crisis.